A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has been approved to treat symptoms of spasticity. In animals, CBD is effective in reducing the amounts of T-cell infiltrates in the spinal cord, suggesting CBD has anti-inflammatory properties. By doing this, CBD has shown to delay symptom onset in animal models of multiple sclerosis and slow disease progression. Importantly, combinations of CBD and Δ9-THC appear more effective in treating animal models of multiple sclerosis. While CBD reduces the amounts of cell infiltrates in the spinal cord, Δ9-THC reduces scores of spasticity. In human studies, the results are less encouraging and conflict with the findings in animals. Drugs which deliver a combination of Δ9-THC and CBD in a 1:1 ratio appear to be only moderately effective in reducing spasticity scores, but appear to be almost as effective as current front-line treatments and cause less severe side effects than other treatments, such as baclofen (a GABA-B receptor agonist) and tizanidine (an α2 adrenergic receptor agonist). The findings of the studies reviewed suggest that cannabinoids may help treat neuropathic pain in pwMS as an add-on therapy to already established pain treatments. It is important to note that treatment with cannabinoid compounds may cause significant cognitive dysfunction. Long term double-blind placebo studies are greatly needed to further our understanding of the role of cannabinoids in multiple sclerosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 1×
“studied the effects of nabiximols on central NP in a randomised control trial [80].”
BackgroundOBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
The cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481 · cited 1×
“This model can be advantageous in inducing a chronic demyelinating disease, as it is characterized by degeneration of oligodendrocytes rather than by a direct attack on the myelin sheath [50].”
BackgroundLangford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298 · cited 2×
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
MethodThe Cuprizone Model: Dos and Do Nots
Zhan, J., Mann, T., Joost, S., Behrangi, N., Frank, M., & Kipp, M. (2020) · Cells · doi:10.3390/cells9040843 · Cited by 208 · cited 1×
“This creates a model that can be used to observe demyelination and remyelination progression at different time points and with gradual effects in different brain areas, and specific manipulations have recently been suggested for the development of this model depending on the exact aims and focus of each study using it…”
MethodMarkovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1481066 · Cited by 151 · cited 1×
“Further supporting the findings of animal studies, Markovà and colleagues studied the effects of Sativex as an add-on therapy in pwMS in a two-phase study design [68].”
ResultDronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136 · cited 2×
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
BackgroundAragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633497 · Cited by 109 · cited 2×
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
BackgroundBiochemically altered myelin triggers autoimmune demyelination
Caprariello, A. V., Rogers, J. A., Morgan, M. L., Hoghooghi, V., Plemel, J. R., Koebel, A., Tsutsui, S., Dunn, J. F., Kotra, L. P., Ousman, S. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721115115 · Cited by 104 · cited 1×
“Rightly, some studies implement a randomised double-blind placebo-controlled study design in a large sample size [88,89], whereas others implement less favourable study designs in smaller groups.”
Backgroundvan Amerongen, G., Kanhai, K., Baakman, A. C., Heuberger, J., Klaassen, E., Beumer, T. L., Strijers, R. L. M., Killestein, J., van Gerven, J., Cohen, A., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.016 · Cited by 86 · cited 3×
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
BackgroundMethodSativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7878-1 · Cited by 66 · cited 2×
“Adverse Event [69] [70] [71] [72] [73] [74] [75] [76] Total”
Result
Cited by
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
The endocannabinoid system: a bridge between alzheimer’s disease and gut microbiota
Bisogno, T., Lauritano, A., & Piscitelli, F. (2021) · Life · doi:10.3390/life11090934 · Cited by 16
“Indeed, the eCB system dysregulation in the CNS has been increasingly implicated in the physiopathology of neurodegenerative and neuropsychiatric disorders, such as AD [18], Parkinson’s disease [34], Huntington’s disease [35], multiple sclerosis [36] schizophrenia [37] and anxiety disorders [38].”
BackgroundCannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review
Carter, C., Laviolette, L., Bietar, B., Zhou, J., & Lehmann, C. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040196 · Cited by 13
Metadata
- Authors
- Jones, É., & Vlachou, S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-10-25
- Volume
- 25
- Issue
- 21
- Pages
- 4930
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3094468438
- Cited by
- 60
- References
- 12
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.